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Decorin, an archetypal member of the small leu-
cine-rich proteoglycan gene family, has a broad
binding repertoire that encompasses matrix struc-
tural components, such as collagens, and growth fac-
tors, particularly those that belong to the transform-
ing growth factor– ligand superfamily. Within the
tumor microenvironment, stromal decorin has an in-
herent proclivity to directly bind and down-regulate
several receptor tyrosine kinases, which are often
overexpressed in cancer cells. The decorin interac-
tome commands a powerful antitumorigenic signal
by potently repressing and attenuating tumor cell
proliferation, survival, migration, and angiogenesis.
This collection of interacting molecules also regulates
key downstream signaling processes indirectly via
the sequestration of growth factors or directly via the
antagonism of receptor tyrosine kinases. We propose
that decorin can be considered a “guardian from the
matrix” because of its innate ability to oppose pro-
tumorigenic cues. (Am J Pathol 2012, 181:380–387; http://
dx.doi.org/10.1016/j.ajpath.2012.04.029)
Neoplastic growth has long been viewed in the paradigm
of activating mutations in oncogenes and silencing of
tumor suppressor genes that confer, collectively over
time, selective advantages to fundamental cellular pro-
cesses such as cell proliferation, survival, migration, and
metastasis. However, relatively recently, the profound im-
portance of the surrounding tumor stroma, encompass-
ing that of abnormal synthesis and deposition of several
proteoglycans, has emerged as an active participant in
coordinating many aspects of tumor growth and progres-
380sion. Indeed, an early defining histopathological feature
of certain carcinomas is the presence of a strong des-
moplastic reaction surrounding the tumor proper that is
inherently enriched in various proteoglycan species.1,2
Decorin represents a prototypical member of the small
leucine-rich proteoglycan (SLRP) gene family that houses
18 distinct members segregating into five discrete classes
with sequence conservation across multiple species.3
Decorin contains a single glycosaminoglycan (GAG)
chain composed of either dermatan or chondroitin sul-
fate, and 12 leucine-rich repeats comprising the protein
core. Decorin is a stromal proteoglycan synthesized
chiefly by fibroblasts, stressed vascular endothelial cells,
and smooth muscle cells. Initially, decorin was named for
and characterized by its high-affinity interactions with
collagen fibers and for the subsequent regulation of col-
lagen fibrillogenesis.4–7 It was subsequently discovered
that decorin sequesters multiple growth factors, such as
transforming growth factor (TGF)–1, and directly antag-
onizes several members of the receptor tyrosine kinase
(RTK) family, including the epidermal growth factor re-
ceptor (EGFR), the insulin-like growth factor receptor I
(IGF-IR), and the hepatocyte growth factor receptor
(Met)1 (Figure 1). Consequently, these latter bioactivities
have been attributed to evoke potent tumor repression.
The unique nature of this repressive activity is that it
functions wholly within the extracellular matrix to attenu-
ate, in an integrated and protracted fashion, key pro-
survival, migratory, proliferative, and angiogenic signal-
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implicated in modulating inflammatory responses as they
pertain to cancer progression via engagement of Toll-like
receptors (TLRs).8 Moreover, reduced decorin within the
tumor stroma has been established as a poor prognosti-
cator of invasive breast cancer and in murine models of
spontaneous breast cancer with mammary gland carci-
nogenesis.2 Endogenously, certain neoplasms have a
proclivity to hypermethylate the decorin promoter, effec-
tively silencing expression and allowing tumor progres-
sion.2,9 Thus, loss of decorin expression may also favor
tumor growth. In this review, we propose the concept of
decorin as a “guardian from the matrix”—that is, a pow-
erful endogenous tumor repressor acting in a paracrine
fashion to limit tumor growth and angiogenesis.
Decorin Modulates Tumor Inflammatory
Properties of the Stroma
A rapidly emerging hallmark of cancer involves inflam-
matory processes as active and critical participants in
tumorigenesis.10 Several articles have been published to
indicate an immunomodulatory role of decorin to recruit
monocytes to injury sites by induction of MCP-1,11 inhib-
iting apoptotic death of macrophages,12 and modulating
allergen-induced asthma.13 A recently identified mecha-
nism was elucidated, linking decorin, inflammation, and
tumor growth.8 This process entails direct binding of sol-
uble decorin to TLR 2 and 4 on macrophages, leading to
enhanced production of the pro-inflammatory protein
programed cell death 4 (PDCD4) and the oncomir miR-
21, thus causing stabilization and increased translation of
PDCD4. The increased abundance of PDCD4 concur-
rently causes a decrease of anti-inflammatory cytokines
such as interleukin (IL)–10 (Figure 2). As an endogenous
inhibitor of TGF1 by sequestration (Figure 1), decorin
Figure 1. Decorin interactome, encompassing growth factors, receptors,
and putative extracellular matrix components to which decorin physically
binds through high-affinity interactions and regulates either negatively or
positively. Additional details are provided in the text.also attenuates TGF1 signaling pathways, thereby fur-ther curbing tumor growth and inflammation.8 Thus, by
antagonizing TGF1, decorin circumvents PDCD4 trans-
lational repression to generate a pro-inflammatory tumor
microenvironment. It also induces the synthesis of pro-
inflammatory modulators (eg, TNF, and IL-12b) for the
suppression of tumorigenic growth. It is important to note
that TNF is a binding partner for decorin14 (Figure 1)
and shows a moderate affinity for this ligand, thus high-
lighting an important regulatory function to further modify
TNF activities.
Recent experiments using an animal model of de-
layed-type hypersensitivity in decorin-null mice are also
supportive of a role of decorin for stimulating a more
pro-inflammatory environment.15 In this setting, lack of
decorin is associated with reduced TNF levels, and
increased expression of leukocyte adhesion molecules
coincides with an increased adherence of leukocytes to
the endothelium.15 Finally, the closest relative of decorin,
biglycan, has been previously shown to modulate im-
mune responses16,17 by acting as an endogenous ligand
for TLR-2/4 to increase pro-inflammatory signals. Thus,
these studies offer a new functional paradigm for SLRPs
and inflammation.
Decorin Curbs the Lethality of the Tumor
Niche
Decorin has exquisite binding affinities for members of
the TGF superfamily (Figure 1), including TGF1,
TGF2, and myostatin,1,2 and through this interaction can
effectively trap ligands within the matrix and indirectly
attenuate downstream signaling pathways mediated by
the TGF receptor complex, as recently shown in a mu-
rine model of hepatic fibrosis.18 However, bone-derived
decorin seems to enhance TGF activity.19 This finding
has broad implications on tumorigenicity, as it can advo-
cate tumor immunosuppression and growth retarda-
tion.20 However, it is not known whether decorin influ-
Figure 2. Broad receptor antagonism and attenuation of downstream sig-
naling cascades mediated by decorin in tumor cells. Antiproliferative, immu-
nomodulatory, and antiangiogenic properties are regulated after engagement
of decorin to cell surface receptors. A detailed discussion of pathway mod-
ulation is provided in the text.
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collagen fibers. In the case of myostatin, decorin seques-
tration quenches myostatin growth inhibitory effects and
thus promotes myoblastic growth in vitro.21 In an analo-
gous antagonistic activity, direct sequestration of
platelet-derived growth factor (PDGF) results in a po-
tent decrease of PDGF-dependent phosphorylation of
the PDGF receptor and attenuation of PDGF-evoked
cellular migration.22
Decorin binds to low-density lipoprotein receptor–re-
lated protein 1 (LRP-1) and causes endocytosis of the
complex, leading to PI3K activation and indirect cross-
talk and modulation of TGF signaling via Smad 2/3/7.23
Although the interaction with LRP-1 has not yet been
evaluated in cancer models, it could have implications for
tumor cell bioenergetics.
Another binding partner of decorin is Wnt-1–induced
secreted protein 1 (WISP-1), a protein mainly confined to
the stroma of colon tumors.24 Decorin binding to WISP-1
results in an inhibition of WISP-1 interactions with other
partners, thus suggesting a regulatory function of decorin
in Wnt signaling.24 It is not known whether WISP-1 activity
is further modulated or antagonized in either a Wnt-1–
dependent or –independent manner by decorin in colon
tumors. Notably, decorin down-regulates -catenin in a
non-canonical way after binding to Met,25 and decorin-
null mice have increased -catenin levels in the intestinal
epithelium.26
In addition to the aforementioned interactions and at-
tenuation of growth factors by direct binding, decorin
also binds a multitude of structural components within the
extracellular matrix, particularly numerous collagen mol-
ecules, tenascin X27, and elastin28 (Figure 1). Aside from
binding fibrillar collagens I, II, and III, decorin also binds
saturably to collagen XIV. Thus, decorin may mediate
binding to fibril-forming collagens while simultaneously
affecting collagen XIV biology. Analyses of the supramo-
lecular composition of collagen VI complexes have de-
termined that decorin and matrilin directly bind to link
collagen VI to either aggrecan or collagen type II fibrils.29
Taking these findings together, it seems plausible that
decorin can certainly participate in regulating desmo-
plastic reactions and higher-order matrix structure forma-
tion in the tumor stroma. The abundant presence of
decorin in the tumor stroma of solid tumors has been
proposed to represent a negative-feedback loop on the
activity of adjacent RTKs expressed by growing malig-
nant cells.1
Decorin Is an Endogenous Pan-Receptor
Tyrosine Kinase Inhibitor
The initial finding that decorin bound with avid affinity to
RTKs (Figure 1) heralded a paradigm shift in the study of
SLRPs and their contributions to cancer biology. EGFR
was the first RTK discovered to bind decorin30 and was
considered the primary target of decorin in various types
of cancer cells,2 as it triggered dimerization, internaliza-
tion via caveosomes, and ultimately the degradation of
the receptor complex within lysosomes,31 presumablyterminating EGFR signaling. This finding is in contrast to
EGF–EGFR complexes that are competent to signal from
endosomes after internalization where EGF is still capa-
ble of maximally stimulating tyrosine phosphorylation.
Furthermore, this stimulation engages several signaling
pathways, such as PLC-1, that are required for cell
motility.32 However, it is currently unknown whether
decorin is proficient to stimulate signaling postinternal-
ization in a fashion analogous to that of EGF.
Systemic delivery of decorin, or viral vectors express-
ing decorin, affects the growth of several types of solid
cancers in which RTKs play key roles.33–36 Paramount to
this feature is the ability of decorin to compete with EGF
and to exert a potent physiological down-regulation of the
receptor at the cell surface of tumor cells.2 However, in
2009, a new target of decorin was discovered via the use
of an RTK phosphotyrosine array, which clearly demon-
strated a rapid burst of phosphorylation of Met.37 It was
further shown that Met is the main target of decorin in
HeLa cells, as inhibition of the kinase domain of EGFR
with the small molecule inhibitor AG1478 or with the
monoclonal blocking antibody mAb425 did not block the
down-regulation of Met evoked by decorin. Moreover,
Met exhibits a higher binding affinity for decorin when
compared with that of EGFR.37
It is a curious biological feature of decorin to evoke
differential phosphorylation signatures in EGFR and Met
on binding. This observation might reflect altered struc-
tural conformations of the receptors postbinding relative
to the active conformation that the receptor adopts after
binding natural ligands. EGFR, for example, undergoes
rapid phosphorylation to stimulate the MAPK signaling
cascade, which paradoxically aids in cell cycle arrest
and caspase-3 activation38 despite total EGFR levels de-
creasing up to 50%.2 Further proof-of-concept for this
phenomenon involves Met. A rapid burst of phosphory-
lation of the tyrosine residues of the intracellular tail of Met
ensues and lasts up to 30 minutes, whereas increased
phospho-Y1003 recruits the E3 ubiquitin ligase c-Cbl for
receptor internalization and degradation.37 It is possible
that these signatures, particularly that of Met, has biolog-
ical significance to convey the properties of decorin bio-
activity. However, at this time, experimental evidence to
evaluate these differential phosphorylation patterns is
lacking but would be essential to gain a more mechanis-
tic understanding of the biology of decorin. This is of
critical importance, considering the lack of endogenous
ligands for Met, which, at present, include only hepato-
cyte growth factor (HGF), internalin B, and decorin.37,39
Along these same lines, engagement of HGF with Met
induces association of the receptor complex with clath-
rin-coated pits40 in HeLa cells for endosomal sorting and
eventual recycling to the plasma membrane. However,
this is not the case for decorin, as it drives caveolin-1 to
associate with Met40 and concomitant lysosomal degra-
dation in the same fashion as EGFR. Clearly, the differ-
ential phosphorylation patterns are encoding messages
pertinent for decorin activity to selectively dictate finite
biological outcomes.
Additional members of the Erb family of RTKs are also
affected by decorin via degradation and signal suppres-
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of EGFR away from functional signaling complexes com-
posed of ErbB2 or ErbB4 heterodimers. However, new
findings indicate a direct antagonism of ErbB4 signaling
by decorin.41 During scar tissue repair in the central
nervous system, employment of small molecule inhibitors
and siRNAs specific for ErbB4 also blocks the decorin-
mediated down-regulation of semaphorin 3A, a target of
ErbB4 activity.41
Opposing roles of decorin in the signaling cascades of
endothelial cells have also been documented. Because
decorin binds collagen with nanomolar affinity, it has
been reported that an interaction among 21 integrin,
collagen type I, and decorin increases endothelial cell
migration by enhancing integrin–collagen interactions.42
However, VEGF-R2 has been reported to be antagonized
by decorin and, more specifically, by an engineered frag-
ment encoding LRR5 via downstream attenuation of
ERK1/2 signaling in human extravillous trophoblastic
(EVT) cells.43
A recurring theme concerning this form of receptor
antagonism is the concept of receptor internalization and
degradation evoked by decorin for most of the RTKs
studied so far. However, this is not the case for IGF-IR, in
which decorin binds to and attenuates the downstream
signaling of IRS-1 and blunts IGF-I activation of Akt, ERK,
and p70S6K, culminating in a migratory block.44 In this
case, decorin does not promote association of IGF-IR
with caveolin-1 but is capable of preventing IGF-I from
localizing IGF-IR to caveosomes. Consequently, this re-
ceptor complex is not internalized or degraded in cellular
models of urinary bladder carcinoma.44 In contrast, in
other cellular systems using non-transformed cells,
decorin seems to be an agonist of IGF-IR.45,46
Collectively, decorin can be considered an endoge-
nous matrix-centric pan-RTK inhibitor that exhibits hierar-
chical binding affinities for various RTKs expressed at a
given time by a tumor cell. This might aid in cross-talk
signal integration, as decorin would be able to bind mul-
tiple receptors with varying kinetics as a mechanism to
subdue growth signals for tumor growth arrest. Further-
more, a common thread uniting these receptors, with the
exception of 21 integrin, is the inclusion of Ig-like mod-
ules in their ectodomain. It is possible that decorin has an
inherent ability to bind all receptors harboring this partic-
ular domain. However, these binding events and poten-
tial biological outputs have not yet been experimentally
evaluated.
Decorin Antagonizes Tumorigenesis by
Attenuating Multiple Signaling Pathways
Robust and high-affinity binding concurrent with rapid
receptor internalization and degradation underlie the ini-
tial events for decorin-mediated tumor growth repression
in relation to broad RTK antagonism (Figure 2). Subse-
quent to this binding, a potent attenuation of multiple
pathways coordinating proliferation, survival, and angio-
genesis ensues. Decorin-mediated antagonism of Met
specifically leads to a non-canonical repression of-catenin and Myc.40 HGF, signaling via Met, enhances
-catenin stability by two distinct modes, including direct
phosphorylation of -catenin47 and concomitant repres-
sion of glycogen synthase kinase 3 (GSK3) via phos-
phorylation. This is an example of RTK-mediated stabili-
zation of -catenin independent of traditional Wnt
signaling. Collectively, this cascade promotes nuclear
translocation of -catenin, which drives transcription of
prosurvival and protumorigenic genes.10 Myc, a target of
-catenin and downstream of HGF/Met,1 coordinates
large networks conducive to growth and proliferation.
Interestingly, among the repertoire of Myc targets is AP4,
a transcriptional repressor of p21WAF148, a cyclin-depen-
dent kinase inhibitor that is specifically induced by
decorin treatment of various cancer cells.1 Conversely,
addition of exogenous decorin induces a profound and
maintained suppression of -catenin and Myc, leading to
inhibition of several key Met-mediated pathways, includ-
ing migration, proliferation, survival, and scattering. This
is mediated in part by relieving RTK inhibition of GSK3,
which in turn phosphorylates Myc at specific sites.40
Phosphorylation of Thr58 on Myc by GSK3 is known to
evoke Myc degradation via the proteasome. Notably,
phosphorylation at this site is markedly induced by the
soluble decorin protein core, coincident with nuclear
translocation, and 26S proteasomal degradation.40 It is
tempting to speculate that protein phosphatase 2A, the
serine–threonine phosphatase directly opposing GSK3,
might also be attenuated, thereby allowing enhanced
-catenin and Myc degradation. This would lead to de-
repression and subsequent induction of the p21 locus
while providing a mechanism for growth arrest (Figure 2).
In addition, -catenin drives cyclin D1 expression, and
this pathway is also antagonized by decorin.40
Recently, a physical interaction between the armadillo
repeats 10–11 of -catenin and the forkhead domain of
FoxM1 was identified as crucial for Wnt3a-directed
-catenin nuclear translocation and assembly of the ter-
nary complex on promoters of target genes.49 Hyperac-
tivation of FoxM1 occurs primarily in various gastrointes-
tinal tumors,50 where it is now believed to facilitate
aberrant -catenin activation. This is intriguing insofar as
decorin-null mice exhibit abnormal intestinal tumor forma-
tion when exposed to a Western diet, showing increased
levels of -catenin.26 It is thus plausible that decorin in
the intestine represents a safeguard against the improper
activity of the FoxM1/-catenin signaling axis.
A connection might exist between decorin and a genomi-
cally imprinted tumor suppressor known as paternally ex-
pressed gene 3 (Peg3). First, morpholino-induced depletion
of decorin in a zebrafish model results in stunted head-to-
tail growth, strongly suggesting a role for decorin in regu-
lating convergent extension,51 a fundamental developmen-
tal process mediated primarily by -catenin signaling via
the planar cell polarity pathway. Interestingly, Peg3 de-
creases -catenin expression, thereby inhibiting ze-
brafish tail development in a Wnt-dependent manner52
and indicating a possible relationship between decorin
and Peg3. This connection is further reinforced by the
observation that the molecular interaction between the
Peg3 N-terminal domain and -catenin is the basis for
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ing.52 This is very analogous to the GSK3- and Wnt-
independent antagonism of -catenin protein orches-
trated by decorin via Met in various tumor cell lines. In the
context of tumor progression, this potential link between
decorin and non-canonical -catenin attenuation might
prove crucial, as there is a strong inverse association
between decreased Peg3 mRNA expression and glio-
blastoma progression and grade.52
A new study has evaluated the role of Wnt signaling in
promoting a supportive hematopoietic niche for stem cell
and progenitor development.53 Importantly, Wnt3a was
found to potently and consistently induce decorin expres-
sion in co-culture models. Furthermore, it was demon-
strated that mesenchymal stem cells, derived from the
bone marrow, act as decorin-producing cells.53 Surpris-
ingly, decorin seems to phenocopy almost all of the same
biological effects of Wnt3a, including stimulation of c-Kit
expression, blockade of B-cell lymphopoiesis, and main-
tenance of undifferentiated hematopoietic stem/progeni-
tor cells.53 These data indicate an intricate role of decorin in
modulating the hematopoietic microenvironment by mim-
icking, instead of opposing, in a non-canonical fashion,
downstream effects promoted by canonical Wnt signaling.
Decorin Affects the Angiogenic Network
A key step in malignant tumor progression is neo-vascu-
larization, beginning with activation of the angiogenic
switch. The molecular components and mechanisms in-
volved are beginning to come into clear focus. However,
the role of decorin in tumor angiogenesis is quite contro-
versial, with studies indicating a pro-angiogenic role such
as enhanced endothelial cell migration via increased
21 integrin interaction with collagen type I42. However,
a recent study has clearly shown an inhibitory and high-
affinity binding of decorin to the VEGF receptor 2
(VEGFR2).43 The intricacies of decorin in regulating angio-
genesis are even more complex in the cornea, where pro-54
and antiangiogenic roles55 exist. Again, we stress the fact
that these studies reporting pro-angiogenic activity of
decorin are typically seen in normal, non-tumorigenic
settings. In contrast, as it pertains to tumor angiogenesis,
decorin, applied as an exogenous or endogenous agent,
exerts powerful angiostatic activities to curtail vascular-
ization in a variety of tumor cell lines56 and inversely
correlates with the extent of vascularization.57
Stromal decorin is able to directly abrogate the HGF/
Met signaling axis to inhibit VEGF-mediated angiogene-
sis58 by transcriptionally repressing hypoxia-inducible
factor1 (HIF-1), -catenin, Myc, and SP1 under nor-
moxia, and non-canonically suppressing HIF-1 pro-
tein.58 This net repression of critical transcription factors
impairs HGF/Met-driven VEGFA. Moreover, Sp1 requires
p42/44 mitogen-activated protein kinase (MAPK)–depen-
dent phosphorylation for competent localization and ac-
tivation of VEGF transcription, which is presumably atten-
uated via RTK antagonism.40,58 Further repression of
VEGF occurs through the attenuation of matrix metallo-
proteinase (MMP) 2 and 9 transcription, which also de-pends on -catenin. This disallows matrix-bound VEGFA
from engaging VEGFR2 on endothelial cell surfaces.58
Abrogation of HGF/Met in vivo provides mechanistic
evidence for the action of decorin. In stark contrast to
HGF, which promotes angiogenesis through positive
VEGF and negative thrombospondin regulation,59
decorin retards angiogenesis by negative VEGFA and
positive thrombospondin regulation. Indeed, in vivo stud-
ies demonstrate that decorin can subvert HGF signaling
through Met to achieve reduced tumor vascularization
and vessel density.58
Through degradation of -catenin and HIF-1, several
intertwined feedback loops are interrupted. Potent loss of
HIF-1 results in reduced expression of Met,58,60 thus
compromising the ability of tumor cells to respond to HGF
signaling. This is further enhanced by the well-docu-
mented notion that HGF/Met potentiates -catenin signal-
ing and Myc expression.1 Thus, decorin silences this
important feedback loop for sustained cellular growth
while mitigating the overall migratory, proliferative, and
angiogenic capacity of malignant cells. Collectively,
these findings indicate a tripartite attack on Met, includ-
ing ectodomain shedding,37 despite TIMP3 induction,
caveolin-mediated endocytosis and degradation,40 and
disruption of positive-feedback loops.58 This is of para-
mount importance because decorin is one of only two
known mammalian ligands for Met, the third being in-
ternalin B, a bacterial protein.39
Decorin can simultaneously induce endogenous angio-
genic inhibitors, such as TIMP3 and thrombospondin-1,
which act to enhance the blockade of VEGF signaling via
HGF/Met (Figure 2), consistent with suppressing Met ac-
tivation to alleviate thrombospondin-1.59 The ramifica-
tions and implications of normoxic attenuation of HIF-1
open multiple possibilities of modulating pertinent path-
ways that are active in the early stages of tumor devel-
opment by circumventing the engagement of the angio-
genic switch. An intriguing possibility relates to HIF-1 in
orchestrating a metabolic adaptation that drives tumor
vascularization, thus linking decorin to possibly modulate
tumor metabolism before the onset of angiogenesis at
early normoxic stages.
Relatives of Decorin in Tumorigenesis:
Lumican and Biglycan
Related members of the SLRP family include lumican
(class II) and biglycan (class I), which share 26% and
57% homology with decorin, respectively. Lumican is a
keratan sulfate proteoglycan that is normally found within
the cornea. It was recently discovered that lumican is
highly expressed within the stroma of high-grade breast
cancers, while exhibiting an altered expression pattern in
various other tumor types.1 Interestingly, the biological
and prognostic correlates of lumican, classified as either
a pro- or antioncogenic agent, within the varied tumors is
certainly diversified, given that specific tumors (eg, colo-
rectal, pancreatic, and pulmonary) exhibit poor prognos-
tic outcomes as lumican expression increases within the
stroma, which is typically indicative of advanced tumors.
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decreased lumican expression correlates with increased
tumor progression,1 suggesting that lumican is antion-
cogenic. This apparent discrepancy for lumican func-
tion among different tumor types is reminiscent of the
context-dependent function of decorin in angiogene-
sis, thus highlighting the complex intricacies of SLRPs
in tumorigenesis.
Lumican induces cell cycle arrest by inducing the cy-
clin-dependent kinase inhibitor p21, decreasing the ac-
tivity and abundance of multiple cyclins, including cyclin-
D1, and activating pro-apoptotic pathways61 akin to
decorin. Furthermore, lumican evokes antimetastatic
properties via high-affinity binding to the 2 I domain of
the 21 integrin, thus suggesting a mechanism of ac-
tion. In parallel, decorin binds to and antagonizes Met,
resulting in decreased migratory capacity and impaired
cellular proliferation and survival. Finally, lumican and
decorin are both capable of inhibiting metastasis.35,36,62
Biglycan, the most closely related SLRP family mem-
ber to decorin, has a very limited involvement in cancer
progression. Primarily pro-inflammatory via TLR2/4 sig-
naling, a study has implicated biglycan overexpression
within human pancreatic cancer tissue as accompanied
by a concomitant induction of p27 and decrease in cyclin
A and PCNA,63 thereby resulting in an inhibition of tumor
growth. Despite the relatively high degree of homology, it
is interesting that decorin and biglycan do not have more
extensive overlapping functions in tumorigenesis.
Conclusion and Perspectives
Decorin, an archetypal small leucine-rich proteoglycan,
possesses intrinsic and potent antitumorigenic capabili-
ties. Initially characterized as an avid binding partner of
collagen and an inherent regulator of fibrillogenesis, sol-
uble decorin is now emerging as a pan-RTK inhibitor
coincident with powerful downstream signaling attenua-
tion. Because of its highly promiscuous and broad bind-
ing repertoire with extracellular matrix constituents,
growth factors, and cell surface receptors, decorin can
be considered a “guardian from the matrix.” Decorin
functions as a guardian in the context of constraining the
activity of multiple growth factors, receptor tyrosine ki-
nases, and extracellular matrix components. The source
of decorin bioactivity lies within the unique attenuation of
potent growth signals and cues that would otherwise
facilitate malignant transformation. Furthermore, in most
cases, these direct protein interactions act to ameliorate
and counteract the overall tumorigenicity of the surround-
ing tumor microenvironment that would also otherwise
foster and promote malignant transformation and tumor
progression. Thus, decorin and perhaps other structur-
ally related SLRPs act at a crossroad between inflamma-
tion and cancer, and could be determinant players in
combatting many forms of solid tumors in which RTKs are
deregulated.64
In addition, we can draw a comparison between
decorin action outside cells with that of transcription fac-
tors inside cells. Several transcription factors, such asp53 and Myc, coordinately regulate the expression of
large subsets of genes that are crucial for the viability of
cellular processes, whereas decorin regulates growth
factor bioavailability and receptor modulation within the
extracellular milieu. Notably, the genetic cooperation be-
tween decorin and the tumor suppressor p53, which is
widely regarded as the “guardian of the genome,” has
already been established insofar as germline-null muta-
tions in the decorin and p53 genes cause enhanced
lymphoma tumorigenesis.65 Thus, it is plausible to con-
nect stromal decorin to the intracellular regulation of the
expression of a large genetic network.
One of the challenges of future research is finding
and isolating the leucine-rich repeats of decorin that
harbor distinct bioactivities. This could be of great
clinical interest in regard to adjuvant peptide thera-
pies. Further engineering of these smaller domains to
specifically target cognate receptors could underlie
advanced therapeutic drug designs that could serve
as potent additions to the growing armamentarium of
matrix-derived cancer modalities.
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